Producing usher III retinal organoids from patient cells to measure the effect of drug candidate
Active Awarded Last action
- Contract number
- 75N91025F00020
- Awardee
-
Leidos Biomedical Research Inc. UEI HV8BH9BPG8Y9 Part of Leidos Holdings, Inc.
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $1,081,521
Award facts
- Contract value 100% obligated
- $1,081,521.00 Current and potential, with all options
- Completion date 32% complete
- Current and potential, with all options
- Funding agency
- National Center for Advancing Translational Sciences National Institutes of Health, Department of Health and Human Services
- NAICS code
- 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Cost Plus Fixed Fee
- Place of performance
- Frederick, MD 21702, USA
- Legislative mandates
-
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
- Service Contract Inventory FAR subpart 4.17
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Other Administrative Action | $286,678 | |
| Other Administrative Action | $0 | |
| Original award | $794,843 |
About this award
The National Center for Advancing Translational Sciences issued a delivery order to Leidos Biomedical Research Inc. on September 15, 2025, with a ceiling value of $1,081,521 for production of USHER III retinal organoids from patient cells to measure the effect of drug candidates.
Leidos Biomedical Research Inc. operates as a Federally Funded Research and Development Center (FFRDC) contractor supporting the National Institutes of Health and National Cancer Institute. Place of performance is Frederick, MD. The order is priced on a cost-plus-fixed-fee basis with an ultimate completion date of March 15, 2029. No set-aside was applied.
Quick answers
Who was awarded contract 75N91025F00020?
75N91025F00020 was awarded to Leidos Biomedical Research Inc. by National Cancer Institute (National Institutes of Health) on September 15, 2025.
How much is contract 75N91025F00020 worth?
The government has obligated $1,081,521 on 75N91025F00020.
Which agency awarded contract 75N91025F00020?
National Cancer Institute (National Institutes of Health) awarded 75N91025F00020, with funding from National Center for Advancing Translational Sciences (National Institutes of Health).
Is contract 75N91025F00020 an order under another contract?
Yes. 75N91025F00020 is a delivery order under 75N91019D00024, an indefinite delivery contract.
Was contract 75N91025F00020 competed?
The extent of competition for 75N91025F00020 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award